-
- 1800 2010
- EN
-1366x0.jpg)
News
Array
(
[0] => stdClass Object
(
[id] => 1232
[id_crawler] =>
[category_product] => NULL
[thumbnail] => iso_27001/chung_nhan_iso_27001.jpg
[album] =>
[url_video] =>
[is_status] => 1
[is_featured] => 0
[is_form] => 0
[displayed_time] => 2024-07-31
[program] => 0
[number] => 1
[viewed] => 0
[type] =>
[type_career] =>
[level] =>
[address] =>
[address_career] =>
[expiration_time] => 0000-00-00
[created_time] => 2024-07-31 14:05:45
[updated_time] => 2024-07-31 14:40:32
[files] =>
[salary] =>
[time] =>
[created_by] => 63
[is_table_content] => 1
[language_code] => en
[slug] => gentis-achieves-isoiec-270012022-certification-affirming-commitment-to-customer-information-security
[title] => GENTIS Achieves ISO/IEC 27001:2022 Certification: Affirming Commitment to Customer Information Security
[description] => On July 24, 2024, Genetic Testing Service Joint Stock Company (GENTIS) officially received the ISO/IEC 27001:2022 certification from Guardian Independent Certification LTD (GICG), a global professional certification organization. This certification is the international standard for information security management systems.
[content] => Achieving ISO/IEC 27001:2022 certification is a significant milestone for GENTIS in affirming the company’s commitment to safeguarding information and ensuring cybersecurity for customers and partners.
ISO/IEC 27001:2022 is the latest version, meeting all the international standards of information security management. This standard sets out specific requirements for establishing, implementing, maintaining, and continuously improving an Information Security Management System (ISMS). ISO 27001’s goal is to protect the confidentiality, integrity, and availability of information through comprehensive risk management measures.
By building and continuously improving a modern information security management system, GENTIS strongly affirms that its information security management system has been and will continue to be operated strictly in compliance with stringent international standards:
- Comprehensive Information Protection: Ensuring that all information of customers, partners, and the company is confidential, integral, and always available.
- Increasing Customer and Partner’s Trust: ISO/IEC 27001:2022 certification is evidence of GENTIS’s commitment to information protection, thereby enhancing trust and credibility from customers and partners.
- Enhancing Information Security Management Efficiency: Systematic and effective application of information security processes and controls.
- Complying with Laws and Regulations: Ensuring compliance with legal and regulatory requirements related to information security, minimizing legal and financial risks.
GENTIS has undergone a rigorous evaluation process that included multiple stages from risk assessment, establishment of information security controls, to training and raising awareness about information security for all employees. The commitment and efforts of the entire team helped GENTIS excellently meet the requirements of ISO 27001:2022.
Achieving this certification is a significant effort by the entire GENTIS team, who worked together to complete the management processes according to the ISO/IEC 27001:2022 requirements after numerous stringent audits. The ISO/IEC 27001:2022 certification is not only a great achievement but also a motivation for GENTIS to continue improving and developing more robustly in the future.
GENTIS is committed to relentlessly maintaining and improving its Information Security Management System according to international standards. We will tirelessly strive to gain absolute trust in our customers and partners.
This event is significant in the medical field, especially in genetic research and cancer treatment. In 2024, the conference will focus on the theme: "Cancer Genetics and Updates on rêcnt advances in Medical Genetics and Genomics" This theme attracts the attention of leading experts, doctors, and researchers from domestic as well as international.
The conference provides a valuable opportunity for GENTIS to accompany, share, and learn about the latest advances in the genetics and cancer field, aiming to improve the quality of healthcare for patients.
The conference will take place over two days with approximately 40 high-quality scientific reports and lively discussions. Notably, Dr. Pham Dinh Minh, Director of the GENTIS Genetic Counseling Center, will present a scientific report on "Application of NGS in preimplantation screening for embryonic microdeletions and duplications."
As the main sponsor of the conference, GENTIS's booth will feature many special activities such as mini-games, and a lucky spin with many attractive gifts to welcome experts and doctors to visit and experience.
GENTIS looks forward to the interest and companionship of experts, doctors, and scientists to contribute to improving treatment quality and the continuous advancement of the healthcare sector.
As of late, GENTIS has announced 4 genetic cancer screening packages namely: LADYCARE, MENCARE, PRE-CARE, and PRO-CARE aimed at helping customers safeguard their health and that of their loved ones.
THE IMPORTANCE OF CANCER SCREENING
Cancer has always been the most dangerous disease for humans today. In 2020, Vietnam estimated 182,563 new cases and 122,690 deaths from cancer. With 159 new diagnoses and 106 cancer-related deaths per 100,000 people, Vietnam’s rates have risen significantly, ranking 90th for new cases and 50th for cancer-related deaths among 185 countries compared to statistics from 2018.
Various preventive measures have been encouraged, and among them, hereditary cancer screening is the most effective method for early detection of cancer risks even before symptoms appear, enabling tailored plans. Recognizing huge interests of the people, GENTIS has introduced hereditary cancer screening packages tailored to customer needs. 
GENETIC CANCER SCREENING PACKAGES AT GENTIS
GENTIS offers 4 advanced cancer screening solutions to detect abnormalities related to cancer early:
- LADYCARE: Screening 10 genes associated with the 3 most common hereditary cancers in women: breast, ovarian, and colorectal cancer.
- MENCARE: Screening 10 genes associated with the 3 most common hereditary cancers in men: prostate, colorectal, and stomach cancer.
- PRE-CARE: Screening 17 genes associated with the 15 most common hereditary cancers in both genders.
- PRO-CARE: Offers comprehensive screening with 133 genes associated with the 30 most common hereditary cancers in both genders.
At GENTIS, these hereditary cancer screening packages help customers and their families to prevent, reduce risks, and proactively plan effective cancer screenings. With dedicated physicians and expert guidance throughout, GENTIS ensures personalized treatment during the whole screening process. Joining GENTIS today to protect your future and your family’s well-being!
[content_more] => [meta_title] => Explore 4 newly genetic cancer screening solutions at GENTIS [meta_description] => As of late, GENTIS has announced 4 genetic cancer screening packages namely: LADYCARE, MENCARE, PRE-CARE, and PRO-CARE [meta_keyword] => GENTIS,Cancer Screening,Hereditary Cancer [thumbnail_alt] => [post_id] => 1230 [category_id] => 4 ) [3] => stdClass Object ( [id] => 1227 [id_crawler] => [category_product] => NULL [thumbnail] => dsc00876.jpg [album] => [url_video] => [is_status] => 1 [is_featured] => 0 [is_form] => 0 [displayed_time] => 2024-07-05 [program] => 0 [number] => 1 [viewed] => 0 [type] => [type_career] => [level] => [address] => [address_career] => [expiration_time] => 0000-00-00 [created_time] => 2024-07-05 14:37:34 [updated_time] => 2024-08-28 14:39:03 [files] => [salary] => [time] => [created_by] => 63 [is_table_content] => 1 [language_code] => en [slug] => Some-issues-to-discuss-in-genetic-counseling-for-PGT-M-testing [title] => Some Issues to Discuss in Genetic Counseling for PGT-M Testing [description] => Preimplantation genetic testing for monogenic/single gene - PGT-M is a groundbreaking advancement that brings hope to having healthy children to families affected by single-gene hereditary conditions. However, genetic counseling for PGT-M testing remains challenging, primarily due to issues in pre-cycle counseling and the expertise and experience of genetic counselors. This was shared by MSc. Nguyen Thi Huyen, M.D (Specialist in Genetic Counseling at GENTIS Genetic Counseling Center) during the ART ADVANCED 11 Seminar with the theme "Controversial Issues in Assisted Reproductive Technology." [content] =>
he Importance of Genetic Counseling in PGT-M Testing for Assisted Reproductive Technology
PGT-M testing allows couples to select genetically healthy embryos for transfer into the mother's uterus, aiming to prevent the risk of passing on hereditary diseases or disease-causing genes to the next generation. This, in turn, helps manage and alleviate the health, financial, and emotional burdens faced by families affected by genetic disorders. The test is indicated for specific single-gene disorders with clearly identified genetic causes.
MSc. Nguyen Thi Huyen, M.D presented a report on Some Issues to Discuss in Genetic Counseling for PGT-M Testing
Before initiating a PGT-M cycle, doctors identify the genetic cause of the disorder, assess the inheritance pattern, and evaluate the genetic risks. They also explain to patients the potential for false negatives and false positives in the test, as well as the benefits, risks, and possible outcomes of agreeing to undergo PGT-M.
To perform PGT-M, couples must undergo in vitro fertilization (IVF) to create embryos. Once the embryos reach the blastocyst stage, a biopsy is conducted (where 3-5 cells are taken from the part of the embryo that will later develop into the placenta). These biopsied cells are then subjected to specialized testing methods to detect disease-causing genetic mutations. If the mother becomes pregnant following a PGT-M cycle, genetic counselors and clinicians will develop a close follow-up plan for her during the pregnancy.
Challenges and Difficulties in Genetic Counseling for PGT-M Testing
In PGT-M testing, genetic counseling is an important process before, during, and after obtaining the results. MSc. Nguyen Thi Huyen, M.D, explained that genetic counseling in PGT-M faces numerous challenges and difficulties. The most common challenge is ensuring that patients understand their condition well enough to make informed and wise decisions. Additionally, the knowledge and experience of the counselor are vital, as they directly impact the amount and quality of information provided to the patient.
Another significant challenge is identifying the genetic mutations responsible for the disorder or understanding the inheritance patterns, as well as the tools needed to detect these mutations. Other factors affecting PGT-M results include how the embryo biopsy is conducted, the technology used, and whether the results meet the initial expectations. All of these factors will depend on thorough, informative and, importantly, individualized genetic counseling that the patient can understand. Therefore, it is essential to have coordinated counseling from clinical experts, embryology labs, and geneticists before, during, and after the testing, so that patients are fully informed of the benefits and limitations of PGT-M, as well as the challenges in embryo screening, embryo transfer, and prenatal diagnosis.
Moreover, counseling on pregnancy follow-up after embryo transfer is also a challenge for clinical doctors. Coordination with obstetricians is needed to manage the pregnancy effectively, and with pediatricians and geneticists after childbirth.
These insights were presented by MSc. Nguyen Thi Huyen, M.D, Genetic Counselor at GENTIS Genetic Counseling Center, during the ART ADVANCED 11 Seminar titled "Controversial Issues in Assisted Reproductive Technology" held on June 29 in Hanoi. The seminar was honored by the participation of leading experts in Andrology, Assisted Reproductive Technology, Obstetrics, along with many doctors from various centers and hospitals who shared knowledge and discussed the latest scientific and technological advancements to improve the effectiveness of infertility treatments.
Dr. Dang Vinh Dung (108 Military Central Hospital) Presents on “Evaluating the Effectiveness of PRP in Treating Patients with Ovarian Failure”
At the workshop, Dang Vinh Dung, M.D, PhD (108 Military Central Hospital) presented the initial results of applying ovarian rejuvenation using platelet-rich plasma (PRP). He emphasized the effectiveness and practical application of this method in supporting the treatment of ovarian failure. GENTIS is honored to have provided scientific information about the PRP IVF kit to Dr. Dung.
As a sponsor of the ART Advanced 11 Seminar, GENTIS hosted many engaging activities for the attending doctors and delegates at their exhibition booth. The experts in attendance highly appreciated the tests provided, researched, and developed by GENTIS.
The GENTIS booth at the ART ADVANCED 11 Seminar garnered significant interest from doctors.
Over the past 13 years, GENTIS has continuously contributed to the development of the reproductive health field in Vietnam. Committed to delivering high-quality products and services, GENTIS consistently strives to support the community and advance the reproductive healthcare sector
[content_more] => [meta_title] => Some Issues to Discuss in Genetic Counseling for PGT-M Testing [meta_description] => Genetic counseling for PGT-M testing remains challenging, primarily due to issues in pre-cycle counseling and the expertise and experience of genetic counselors [meta_keyword] => GENTIS,PGT-M,Testing [thumbnail_alt] => [post_id] => 1227 [category_id] => 4 ) [4] => stdClass Object ( [id] => 1226 [id_crawler] => [category_product] => NULL [thumbnail] => dsc03356.jpg [album] => [url_video] => [is_status] => 1 [is_featured] => 0 [is_form] => 0 [displayed_time] => 2024-07-01 [program] => 0 [number] => 1 [viewed] => 0 [type] => [type_career] => [level] => [address] => [address_career] => [expiration_time] => 0000-00-00 [created_time] => 2024-07-04 15:43:17 [updated_time] => 2024-08-28 14:52:25 [files] => [salary] => [time] => [created_by] => 63 [is_table_content] => 1 [language_code] => en [slug] => Genetics-is-one-of-the-factors-directly-affecting-male-infertility [title] => Genetics is one of the factors directly affecting male infertility [description] => Male infertility is becoming increasingly common, causing men to feel insecure and affecting family happiness. According to Dr. Mai Ba Tien Dung, PhD.MD. (Head of Andrology Department - Binh Dan Hospital, Ho Chi Minh City), “There are many causes of male infertility. Besides mumps, cancer, injuries from conditions such as varicocele, infections, pelvic surgery, etc., genetics is one of the important factors directly affecting male infertility.” [content] =>Current status of male infertility in Vietnam
So far, the stereotype has been that infertility is mainly due to women. However, according to the latest research by the World Health Organization (WHO), infertility causes come from both men and women.
The Andrology session at the 21st Annual Urology and Nephrology Scientific Conference (HUNA) 2024 attracted the attention of many delegates.
In infertility cases, female factors account for 40%, male factors for 30%, both partners for 20%, and 10% remain unexplained. This data shows that the incidence of male and female infertility is similar. This is why, in recent years, male infertility has been a focus of scientific research and patient care in Vietnam.
In fact, the frequency of male infertility in the community is 15%. This is an alarming number, requiring attention and appropriate programs for screening and treating male infertility.
How do genetic factors affect male infertility?
There are many causes of male infertility. Commonly mentioned ones include mumps, cancer, injuries from conditions such as varicocele, infections, and pelvic surgery. Besides, genetics is also one of the factors.
According to Dr. Mai Ba Tien Dung, PhD.MD. (Head of Andrology Department - Binh Dan Hospital, Ho Chi Minh City), genetics is one of the factors directly affecting male infertility. When genetic factors of infertile patients are surveyed, clinicians can provide suitable treatment methods for each specific individual, thereby personalizing and saving treatment costs for patients.
Dr. Dung also stated that genetic issues have started to develop in Vietnam in recent years. However, the number of facilities capable of performing genetic tests for men is still limited in Vietnam. The development, expansion, and popularization of genetic tests are the shared desire of clinicians to support the examination, diagnosis, and treatment of male infertility.
Fertiscan test mentioned by Dr. Mai Ba Tien Dung, PhD.MD. in the scientific report at HUNA 2024
In his scientific report at the 21st Annual Urology and Nephrology Scientific Conference (HUNA) 2024, held on June 27-29 in Rach Gia City, Kien Giang Province, Dr. Mai Ba Tien Dung, PhD.MD. discussed Fertiscan testing. Dr. Dung used Fertiscan testing to identify key genetic factors related to sperm synthesis in patients, thereby shortening the diagnostic process and reducing treatment costs.
HUNA is an annual scientific conference aimed at connecting Vietnamese and international doctors, nurses, and medical experts. This year’s conference had over 1,000 participants, including leading specialists, doctors, and nurses in urology, nephrology, andrology, kidney transplantation, and dialysis from hospitals both within the country and abroad.
Experts Attending the 21st Annual Urology and Nephrology Scientific Conference (HUNA) 2024
At HUNA 2024, GENTIS had the opportunity to learn, exchange experiences, and update new trends and medical advances in diagnosing and treating andrological diseases. With a team of experts having many years of experience in genetic research, along with well-planned investments in new, highly accurate technologies, GENTIS hopes that genetic tests will assist clinicians in screening, diagnosing, identifying the causes of infertility, and finding appropriate treatment methods
[content_more] => [meta_title] => Genetics is one of the factors directly affecting male infertility [meta_description] => “There are many causes of male infertility. Besides mumps, cancer, injuries from conditions such as varicocele, infections, pelvic surgery, etc., genetics is one of the important factors directly affecting male infertility.” [meta_keyword] => GENTIS,Infertility,Male [thumbnail_alt] => [post_id] => 1226 [category_id] => 4 ) [5] => stdClass Object ( [id] => 1223 [id_crawler] => [category_product] => NULL [thumbnail] => 33c3a23bc18e62d03b9f.jpg [album] => [url_video] => [is_status] => 1 [is_featured] => 0 [is_form] => 0 [displayed_time] => 2024-06-26 [program] => 0 [number] => 1 [viewed] => 0 [type] => [type_career] => [level] => [address] => [address_career] => [expiration_time] => 0000-00-00 [created_time] => 2024-06-26 16:02:48 [updated_time] => 2024-08-28 14:48:09 [files] => [salary] => [time] => [created_by] => 63 [is_table_content] => 1 [language_code] => en [slug] => GENTIS-accompanies-the-art-advanced-11-conference-with-the-theme-controversial-issues-in-reproductive-support [title] => GENTIS accompanies the ART ADVANCED 11 conference with the theme "Controversial Issues in Reproductive Support" [description] => The ART ADVANCED 11 conference is organized by the Hanoi Reproductive Support Association. This year, it will focus on the topic “Controversial Issues in Reproductive Support” and feature the participation of many leading experts in this field in Vietnam. [content] =>The ART ADVANCED 11 conference will be held from 08:00 to 16:00 on Saturday, June 29, 2024, at the 1st Floor, Pullman Hanoi Hotel, 61 Giang Vo, Dong Da, Hanoi.
Honored as a sponsor of the conference, the GENTIS booth will offer many special activities and attractive gifts to the esteemed delegates…
Notably, GENTIS representative, Nguyen Thi Huyen, MSc.MD., will present a scientific report titled "Genetic Counseling for PGT-M Testing: Some Issues to Discuss."
We look forward to welcoming esteemed delegates and doctors at the ART ADVANCED 11 conference.
[content_more] => [meta_title] => GENTIS accompanies the ART ADVANCED 11 conference [meta_description] => GENTIS accompanies the ART ADVANCED 11 conference with the theme "Controversial Issues in Reproductive Support" [meta_keyword] => GENTIS,ArtAdvanced,Accompany [thumbnail_alt] => [post_id] => 1223 [category_id] => 4 ) [6] => stdClass Object ( [id] => 1222 [id_crawler] => [category_product] => NULL [thumbnail] => b02b3a36dd4b7e15275a.jpg [album] => [url_video] => [is_status] => 1 [is_featured] => 0 [is_form] => 0 [displayed_time] => 2024-06-12 [program] => 0 [number] => 1 [viewed] => 0 [type] => [type_career] => [level] => [address] => [address_career] => [expiration_time] => 0000-00-00 [created_time] => 2024-06-19 16:36:25 [updated_time] => 2024-09-05 09:24:03 [files] => [salary] => [time] => [created_by] => 63 [is_table_content] => 1 [language_code] => en [slug] => Gentis-launches-the-non-invasive-prenatal-screening-package-geneva-92 [title] => GENTIS launches the non-invasive prenatal screening package GenEva 92 [description] => Recently, GENTIS announced the launch of the GenEva 92 non-invasive prenatal screening package (NIPT IVD), committing to provide the highest quality service for expectant mothers. "With the GenEva 92 test meeting CE-IVD standards and achieving high accuracy of over 99%, GENTIS is confident that this service will become a regular test for expectant mothers in Vietnam in the near future," said Mr. Do Manh Ha, General Director of GENTIS. [content] =>GenEva 92 - A New Advancement in Non-Invasive Prenatal Screening
GenEva 92 is a non-invasive prenatal screening test that screens for syndromes related to fetal genetic abnormalities by analyzing cfDNA from the fetus in the maternal blood starting from the 10th week of pregnancy, ensuring safety and achieving an accuracy rate of over 99%.
NIPT testing is recommended by global medical associations (ACOG, ISPD) for all expectant mothers. In Vietnam, in April 2020, the Ministry of Health issued Decision 1807, officially incorporating the NIPT method into the prenatal screening process. Following this decision, NIPT has become a highly accurate screening test that is trusted and utilized by expectant mothers.
In practice, NIPT testing is becoming increasingly popular in Vietnam, significantly aiding in pregnancy management. As a result, GENTIS continues to enhance its services, utilizing sequenced data analyzed with proprietary software certified CE-IVD to ensure high accuracy. Notably, GenEva 92 is a CE-IVD certified non-invasive prenatal screening solution for the entire process
GenEva 92 - A New Advancement in Non-Invasive Prenatal Screening
Several innovations of the GenEva 92 Test at GENTIS
To implement the GenEva 92 test, GENTIS has invested in and installed advanced equipment and machinery, along with technical training based on rigorous standards. Currently, GENTIS has fully mastered the technology and integrated it into regular testing procedures.
With adopting the GenEva 92 test, expectant mothers will benefit from comprehensive, safe, and accurate screening that minimizes risks for both mother and fetus. Additionally, the testing process is quicker and more efficient, providing peace of mind and significant support for obstetricians and families. GenEva 92 is regarded as an essential tool in modern prenatal care due to its outstanding advantages, including:
- The process is fully automated from sample extraction to result analysis, significantly reducing the need for direct technician intervention. As a result, human error is minimized, leading to more accurate and stable outcomes, with sensitivity and specificity proven to exceed 99%.
- The GenEva 92 test utilizes IVD-certified reagents for the entire process, from the chemicals used to extract cfDNA from maternal blood to the next-generation sequencing reagents.
- The proprietary result analysis software is CE-IVD certified, ensuring high accuracy. This is a significant advantage that currently sets GenEva 92 apart from other NIPT testing packages available on the market.
- The GenEva 92 test offers an expanded testing solution capable of identifying the following abnormalities:
- Three common aneuploidy syndromes: Trisomy 21 (Down syndrome), Trisomy 18 (Edwards syndrome), and Trisomy 13 (Patau syndrome).
- Four syndromes: XO (Turner syndrome), XXX (Triple X syndrome), XXY (Klinefelter syndrome), and XYY (Jacobs syndrome).
- Aneuploidy across all other chromosomes.
- Ninety-two microdeletions/duplications associated with common genetic syndromes, including Prader-Willi/Angelman (15q11.2), DiGeorge (22q11.2), and Cri-du-chat,...
With the GenEva 92 test, GENTIS hopes this will mark a significant turning point in the journey to enhance the quality of healthcare services in Vietnam. GENTIS is committed to continuing research and development to provide the most effective and advanced healthcare solutions for Vietnamese people.
The conference saw the participation of over 500 leading doctors and experts from hospitals, assisted reproduction centers, and testing centers across the country. Representing GENTIS at the event was Mr. Do Manh Ha (CEO) along with a team of product research and development specialists.
The 11th Conference on Infertility and Assisted Reproductive Techniques featured four sessions, including 18 specialized presentations, research reports, and discussions led by top doctors and experts in the fields of reproduction and assisted reproduction in Vietnam. The discussions were lively, with many questions raised and directly addressed.
Dr. Nguyen Van Thong, Specialist level II from Hung Vuong Hospital, with the presentation “Preimplantation Genetic Testing for Microdeletions: Where Do We Stand?”
One notable presentation was by Dr. Nguyen Van Thong from Hung Vuong Hospital, titled “Preimplantation Genetic Testing for Microdeletions: Where Do We Stand?” This presentation received high praise from leading professors and experts in the field. Dr. Thong emphasized the importance of screening and diagnosing microdeletions in embryos, as these abnormalities can cause severe complications, often affecting the intellectual and motor development of children after birth. Moreover, these abnormalities cannot be detected through standard tests like karyotyping, and their occurrence does not vary with maternal age.
Therefore, preimplantation genetic testing (PGT) is considered the optimal solution for selecting genetically healthy embryos, increasing the chances of successful pregnancy through in vitro fertilization (IVF), and ensuring that children are born free from screened genetic syndromes.
Dr. Thong shared that he has utilized the PGT-Max 1 test in real clinical cases at Hung Vuong Hospital.
Dr. Thong further explained, “Preimplantation genetic testing abnormalities are classified into three groups: PGT-A, PGT-M, and PGT-SR. PGT-A is used to diagnose chromosomal aneuploidies, PGT-M is for diagnosing single-gene disorders, and PGT-SR is for detecting structural abnormalities larger than 5Mb. Currently, structural abnormalities smaller than 2-5Mb remain a gray area that we have yet to fully explore.” This highlights the need for solutions to address these uncharted areas.
In response to this need, GENTIS has developed the PGT-Max 1 test, which detects aneuploidies across all 24 chromosomes, structural chromosomal abnormalities (such as duplications and deletions) greater than 5Mb, and certain common microdeletions larger than 2Mb, including the 22q11.2 deletion (related to DiGeorge syndrome), 1p36 deletion (related to 1p36 deletion syndrome), and other common microdeletions. This application offers the highest resolution currently available in Vietnam.
To achieve this breakthrough, the GENTIS research team developed the test using high-resolution Next Generation Sequencing (NGS) technology, surpassing the resolution of standard PGT tests, and applied specialized bioinformatics software capable of detecting microdeletions as small as 2Mb—something not possible with other common PGT tests on the market.
GENTIS’s Involvement in the 11th Conference on Infertility and Assisted Reproductive Techniques
GENTIS is a pioneer in PGT testing in Vietnam, with over 10 years of experience in the field. The company follows a standardized testing process and operates a laboratory system that meets the necessary standards for PGT. GENTIS was the first unit in Vietnam to receive ISO 15189:2012 certification for PGT testing.
Additionally, GENTIS has a team of experienced research and development specialists who continuously update the latest features of PGT tests. This is essential for the future, as it will allow for the development of higher-resolution PGT tests capable of detecting more abnormalities. The ultimate goal is that every embryo transferred is the best possible one, increasing pregnancy success rates and ensuring the birth of healthy babies.
[content_more] => [meta_title] => GENTIS Participates in the 11th Conference on Infertility and Assisted Reproductive Techniques [meta_description] => On June 9, GENTIS attended the 11th Conference on Infertility and Assisted Reproductive Techniques, [meta_keyword] => assisted reproduction,gentis,pgt [thumbnail_alt] => [post_id] => 1221 [category_id] => 4 ) )
GENTIS Achieves ISO/IEC 27001:2022 Certification: Affirming Commitment to Customer Information Security
GENTIS accompanies The 2nd congress of Vietnam Association of medical genetics and genomis and The 4th national science conference - 2024
Explore 4 newly genetic cancer screening solutions at GENTIS
Some Issues to Discuss in Genetic Counseling for PGT-M Testing
Genetics is one of the factors directly affecting male infertility
GENTIS accompanies the ART ADVANCED 11 conference with the theme "Controversial Issues in Reproductive Support"
GENTIS launches the non-invasive prenatal screening package GenEva 92
GENTIS Participates in the 11th Conference on Infertility and Assisted Reproductive Techniques
Quý khách vui lòng điền thông tin bên dưới để được hỗ trợ,
tư vấn một cách tốt nhất!
Xem Socolive trực tuyến tiếng Việt
Link Bóng Đá Lu miễn phí
Link Rakhoi TV bóng đá trực tuyến
Xem tructiep https://xoilaczll.tv/
Link trực tiếp MitomTV bình luận tiếng Việt https://f8betht.baby Xem tructiep https://uniscore.com/vi NEW88 NEW88 789BET 789BET 789BETQuý khách vui lòng điền thông tin bên dưới để được hỗ trợ,
tư vấn một cách tốt nhất!
